Is Boston Scientific (BSX) Undervalued Following Recalls, Cyberattack, And Lower Guidance?

Boston Scientific (BSX) is under close watch after a cluster of company specific shocks. Recent voluntary global device recalls and an ongoing cyberattack related disruption have combined with lower 2026 sales and earnings guidance.

At a last close of US$47.80, Boston Scientific’s 1 day share price return of 1.81% and 7 day share price return of 2.05% offer only a brief respite in a tougher year, with the year to date share price return down 49.53% as recalls and the cyberattack weigh on sentiment and contribute to a 1 year total shareholder return decline of 55.42%.

Spot potential rebounds or steadier alternatives to Boston Scientific by scanning our hand picked 81 resilient stocks with low risk scores, which prioritize resilient balance sheets and more consistent return profiles.

After a share price fall of more than 50% over the past year, Boston Scientific now sits at a very different starting point. Does that reset make sense to treat as an entry today, or is it a situation to watch and reprice first through valuation?

Most Popular Narrative: 23.8% Undervalued

The most followed narrative on Boston Scientific pegs fair value at $62.69 compared with the last close at $47.80. This frames a sizeable valuation gap built on detailed growth, margin and discount rate assumptions.

Accelerated adoption of advanced therapies like FARAPULSE (pulsed field ablation) and WATCHMAN backed by expanded clinical indications, strong safety/efficacy data, and increased physician uptake, particularly in major global markets positions Boston Scientific for continued above market procedure growth, benefiting revenue and gross margins.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap for Boston Scientific? The narrative leans heavily on steady revenue expansion, firmer profit margins and a richer future earnings multiple. Curious which assumptions really move the fair value line?

Result: Fair Value of $62.69 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh ongoing device recalls and reimbursement pressure around Watchman, which could undermine Boston Scientific’s margin assumptions and P/E reset case.

Find out about the key risks to this Boston Scientific narrative.

Next Steps

With sentiment on Boston Scientific clearly mixed, now is a good time to move quickly, review the full risk reward picture, and shape your own view with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Boston Scientific?

If Boston Scientific has your attention, do not stop here. Use the Simply Wall St screener to quickly surface other opportunities that match your investing style.

• Spot potential bargains early by scanning our curated list of value focused ideas through the 47 high quality undervalued stocks.
• Prioritise financial resilience and sleep easier at night by reviewing companies highlighted in the list of solid balance sheet and fundamentals (53 results).
• Target reliable income streams by checking out companies featured in the 11 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com